224 related articles for article (PubMed ID: 32133868)
1. Off-Label Therapeutic Potential of Crisaborole.
Makins C; Sanghera R; Grewal PS
J Cutan Med Surg; 2020; 24(3):292-296. PubMed ID: 32133868
[TBL] [Abstract][Full Text] [Related]
2. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
3. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
4. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Purohit V; Riley S; Tan H; Ports WC
J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
[TBL] [Abstract][Full Text] [Related]
6. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
7. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
8. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
9. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
10. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
12. Utility of boron in dermatology.
Jackson DG; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2020 Feb; 31(1):2-12. PubMed ID: 28789577
[No Abstract] [Full Text] [Related]
13. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
[TBL] [Abstract][Full Text] [Related]
14. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
15. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.
Youn C; Dikeman DA; Chang E; Liu H; Nolan SJ; Alphonse MP; Joyce DP; Liu Q; Meixiong J; Dong X; Miller LS; Archer NK
Exp Dermatol; 2023 Apr; 32(4):425-435. PubMed ID: 36461082
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
17. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
[TBL] [Abstract][Full Text] [Related]
18. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Cheape AC; Murrell DF
Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
[TBL] [Abstract][Full Text] [Related]
19. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
